Motus GI Holdings, Inc. · OTC:MOTS
Motus GI — Investor Presentation (April 2023)
19 slides from Motus GI's investor presentation, April 2023
Slide 1: Breakthrough Visualization Solutions for GI Procedures
Breakthrough Visualization Solutions for GI Procedures April 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company’s product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bu
Slide 3: Motus GI mission and key strengths
Motus GI IP Protection & First Mover Our mission is to provide Advantage Well- innovative visualization Robust Positioned for solutions in GI procedures that Clinical Strategic Results improve patient outcomes and Partnerships experiences. Large Global Experienced Addressable Leadership Markets Team
Slide 4: Executive Leadership Team
Executive Leadership Team Mark L. Pomeranz I Chief Executive Officer, Board Director Andrew L. Taylor, MBA I Chief Financial Officer Yosi Tzabari I VP, Research and Development Jeff Gnagi I VP, US Sales Ravit Ram I VP, Operations & General Manager, Israel Motus GI | Breakthrough Solutions for GI Pro
Slide 5: Large Global Market Opportunity
Large Global Market Opportunity >17.3M 1,2 o Visualization in Emergent Endoscopy, including Upper GI Bleeding is a significant issue that impacts treatment in a patient population with a high Visualization Impaired mortality rate Procedures Annually on a Global basis o Insufficient Bowel Prep (IBP)
Slide 6: Pure-Vu EVS Solution | Novel Technology Ensures Visualization
Pure-Vu® EVS Solution | Novel Technology Ensures Visualization The Pure-Vu EVS system is indicated to help facilitate the cleaning of a GI tract during an endoscopy procedure. This includes clearing blood, blood clots, and debris in the Upper GI tract as well as fecal matter and debris in the Colon
Slide 7: The Unmet Need
The Unmet Need If You Can’t See It, You Can’t Diagnose and Treat It INPATIENT UPPER ENDOSCOPY Patient Admitted Emergency Upper Procedure Aborted – Bleed Site Revealed 2 Hr Procedure Upper GI Bleed Endoscopy Bleed site not revealed And Treated INPATIENT COLONOSCOPY Patient Admitted 24 hr Clear Liquid
Slide 8: Our Solution | 45 Granted Patents Worldwide
Our Solution | Novel Technology Ensures Visualization First Mover Advantage with No Competition PULSED VORTEX SMART SENSE SMOOTH GLIDE IRRIGATION SUCTION NAVIGATION 45 Granted Patents Worldwide Motus GI | Breakthrough Solutions for GI Endoscopy 10
Slide 9: Pure-Vu Demonstrates Effective Intraprocedural Cleansing
Pure-Vu Consistently Demonstrates Effective Intraprocedural Cleansing in Patients with IBP 4 STUDIES In three multi-centered and one single-center studies, patients presenting with an inadequately prepped colon (as determined by 3 PUBLISHED IN PEER- the Boston Bowel Preparation Scale) became adequat
Slide 10: Product Design: Pure-Vu EVS Upper GI and Gen 4 Colon
Product Design: Pure-Vu EVS Upper GI and Gen 4 Colon Streamlined, High Margin with Enhanced Capabilities • Streamlined disposable to Navigate the esophagus Large Suction Lumen • Rapid load design for bedside setup • One large suction lumen (~6x standard gastroscope suction channel area) to remove la
Slide 11: Establishing a Commercial Footprint
Establishing a Commercial Footprint Creating an Installed Base of Hospital Systems / Supports Future Growth 19 Pure-Vu systems installed in 2022 Veterans Affair Hospital Focus 215,000 colonoscopies are performed at ~170 VA medical centers/Yr • High rate of inadequate prep • ~ 50% do not return if ca
Slide 12: A Closer Look at the Pure-Vu EVS US Opportunity
A Closer Look at the Pure-Vu EVS US Opportunity 2023 2024 2025 and Beyond INPATIENT INPATIENT / EMERGENT INPATIENT / EMERGENT COLONOSCOPY COLONOSCOPY COLONOSCOPY UPPER GI ENOSCOPY UPPER GI ENDOSCOPY TARGETED ~$6B *4 HOSPITAL-BASED EXPANDED HOSPITAL-BASED OUTPATIENT HOSPITAL-BASED OUTPATIENT COLONOSC
Slide 13: Key Company Focus
Key Company Focus Building the Foundation for Commercialization Partnerships Establishing the Pure Vu Building Market Scaling Towards Growth Drivers Brand Share Profitability • Strong Brand Awareness • Multiple Hospital System • Value Based Pricing • Upper GI Indication • Published Clinical & Agreem
Slide 14: Key Companies in the GI Space
Key Companies in the GI Space Endoscopy Motus’ Products are Synergistic with Existing and Emerging Technologies Sold by Various GI Companies • Hemostasis • EMR/ESD • AI Polyp Detection • Surgical Endoscopy Pure-Vu EVS Creates Unique Differentiation in the Market • Plays in both UGI and LGI • Easily
Slide 15: Additional Product Expansion Opportunities
Additional Product Expansion Opportunities Pure—Vu Mini • Leverages current development activities • Low cost (<$30 COGS) while maintaining Pure-Vu’s innovative irrigation with smart sense suction through working channel of scopes. • Targeted for outpatient colonoscopy segment, price sensitive marke
Slide 16: Key Upcoming Catalysts in 2023
First in Man for Upper GI Pure Vu EVS Key Upcoming Pure-Vu EVS Upper GI regulatory submission Catalysts in 2023 for indication expansion Gen 4 Pure-Vu EVS Colon regulatory submission with 50% COGs reduction Pure Vu EVS CE Mark / EU-MDR Health System Agreements Motus GI | Breakthrough Solutions for G
Slide 17: Follow Our Journey. Share in Our Success.
Follow Our Journey. Share in Our Success.
Slide 18: Board of Directors
Board of Directors Timothy P. Moran | Chairman Seasoned commercial and operating executive with experience in both large publicly-traded med-tech and private equity-backed organizations David Hochman | Director Chairman, CEO & Founder, Orchestra BioMed Shervin Korangy | Director President and Chief
Slide 19: References
References Slide Reference 5 1. Estimate for calendar year 2021, based on Motus review and analysis of 2019 inpatient market data and 2021 projections for the U.S., as obtained from iData Research Inc. 2. Estimate based on worldwide colonoscopy market data from 2019 and our review and analysis of 20
Motus GI Holdings — Investor Presentation (April 2023) on 6ix